WO1997017850A1 - Hemoregulatory compounds - Google Patents
Hemoregulatory compounds Download PDFInfo
- Publication number
- WO1997017850A1 WO1997017850A1 PCT/US1996/018008 US9618008W WO9717850A1 WO 1997017850 A1 WO1997017850 A1 WO 1997017850A1 US 9618008 W US9618008 W US 9618008W WO 9717850 A1 WO9717850 A1 WO 9717850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- denotes
- cor
- integer
- alkyl
- independently
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 46
- 230000003612 virological effect Effects 0.000 claims abstract description 8
- 230000002538 fungal effect Effects 0.000 claims abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 5
- -1 (CH2)mR4 Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000002431 hydrogen Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 150000002923 oximes Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 230000003525 myelopoietic effect Effects 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 2
- BNDCYQXUFIHUHS-UHFFFAOYSA-N 2,5-dihydropyrazine Chemical class C1C=NCC=N1 BNDCYQXUFIHUHS-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 208000024386 fungal infectious disease Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010065553 Bone marrow failure Diseases 0.000 description 4
- 108010075031 Cytochromes c Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000004235 neutropenia Diseases 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102400000500 GRO-beta(5-73) Human genes 0.000 description 3
- 101500024488 Homo sapiens GRO-beta(5-73) Proteins 0.000 description 3
- 101500028514 Mus musculus KC(5-72) Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- HRAZLOIRFUQOPL-JTQLQIEISA-N (2s)-3,6-diethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound CCOC1=N[C@@H](C(C)C)C(OCC)=NC1 HRAZLOIRFUQOPL-JTQLQIEISA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 0 *C(N)OC(*)N Chemical compound *C(N)OC(*)N 0.000 description 1
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical group BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000490025 Schefflera digitata Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 231100001018 bone marrow damage Toxicity 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-dimethylbenzene Natural products CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
- the haematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter TM. Stem cells in normal growth and disease, Br Med J 1987; 195:1192-1194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclastes and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells, 1988; Harvard University Press, Cambridge, MA). The stem cells are also ultimately responsible for regenerating the bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.
- the risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infections with acute leukemia. Ann In Med 1965; 64:328-334).
- the control of haematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the haematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells.
- G-CSF granulocyte colony stimulating factor
- GM-CSF granulocyte- macrophage stimulating factor
- M-CSF macrophage-colony stimulating factor
- G-CSF granulocyte colony stimulating factor
- G-CSF granulocyte- macrophage stimulating factor
- M-CSF macrophage-colony stimulating factor
- interleukines which have overlapping, additive and synergistic actions which play major roles in host defence. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as well as by the activation of effector cell functions (Moore MAS. Haematopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surveys 1990; 9:7-80).
- These co-ordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.
- G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk patients following bone marrow transplantation (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342:153-157 and Munn DH, Cheung NKV. Preclinical and clinical studies of macrophage colony- stimulating factor. Semin Oncol 1992; 19:395-407).
- This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate haematopoiesis and in the prevention and treatment of bacterial, viral and fungal diseases.
- These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgical induced myelosuppression, AIDS, ARDS, congenital yelodysplacis, bone marrow and organ transplants; in the protection of patients with leukopenia from infection; in the treatment of severely burned patients and in the amelioration ofthe myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals.
- the compounds are also useful in the treatment and prevention of viral, fungal and bacterial diseases, particularly Candida, Herpes and hepatitis
- This invention is also a pharmaceutical composition, which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
- This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
- This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections including sepsis in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
- Ai and A2 independently from each other denote a group Z-(CH2)k-(NR"')q, wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cj_4alkyl, F, Cl, Br, I, Cj_4 alkoxy, (CH2) m R4, oxo, oxime, O-Cj. 4alkyloxime, hydroxy, N(R3)2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded;
- R' and R" are independently hydrogen, C ⁇ _4alkylC(O)R4, C ⁇ _4alkyl or R' and R are benzyl which is optionally substituted by one or two C j ⁇ alkyl, C 1 _4alkoxy, F, Cl, I, Br, OH, or N(R 3 ) 2 ; k is an integer from 0 to 4; R'" denotes Hydrogen, C ⁇ _4-alkyl or C ⁇ .4-alkylcarboxylic acid; q is an integer from 0 to 1 ; Q denotes a group
- Bi denotes halogen, -(CH 2 ) m -CN, -(CH 2 ) m+ i-R 2 , -(CH 2 ) m -R 3 ,- (CH 2 )m- COR 2 or -(CH 2 ) m -COR 3 ;
- R 2 denotes - OR 3 , -N(R 3 ) 2 , - SR 3 ;
- R 3 is independently hydrogen, C -C4-alkyl or benzyl;
- m is an integer from 0 to 4;
- Ci denotes halogen, -(CH 2 ) n -CN, -(CH 2 ) n+ l-R 4 , -(CH 2 ) n -R 5 , -(CH 2 ) n -COR 4 or -(CH 2 ) n -COR 5 ;
- R 4 is independently -OR 5 , -N(R 5 ) 2 , - SR 5 ;
- R 5 is independently hydrogen, C ⁇ -C4-alkyl or benzyl and n is an integer from 0 to 4;
- B 2 denotes halogen, -(CH 2 ) p -CN, -(CH 2 ) p+ ⁇ -R 6 , -(CH 2 ) p -R 7 , -(CH 2 ) p -COR 6 or -(CH 2 ) p -COR 7 ;
- R 6 is independently -OR 7 , -N(R 7 ) 2 , -SR 7 ;
- R 7 is independently hydrogen, C j -C4-alkyl or benzyl;
- p is independently an integer from 0 to 4;
- C 2 denotes halogen, -(CH 2 ) ⁇ -CN, -(CH 2 ) ⁇ + ⁇ -R 8 , -(CH 2 ) ⁇ -R 9 , -(CH 2 )I-COR8 or -(CH 2 ) ⁇ -COR 9 ;
- R 8 is independently -OR 9 , -N(R 9 )2, -SR 9 ;
- R 9 is independently hydrogen, C i -C4-alkyl or benzyl ;
- 1 is an integer from 0 to 4.
- D denotes -(CH2) x -E-(CH2) y -;
- E denotes a mono- or bicyclic aromatic or nonaromatic ring system consisting of 5 - 10 carbon atoms containing up to 4 heteroatoms N, O or S in the ring, which is optionally mono-, poly or mixed substituted by alkyl, alkoxy, oxo, alkoxyalky, hydroxy, amino or dialkylamino and x and y independently denote an integer from 0 to 5; with the proviso that
- Bi is not identical to Ci and B2 is not identical to C2- and Ai ⁇ A2 ;
- Z in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl,
- Possible substituents for Z are C1.4-a.kyl, C ⁇ .4-alko y, C ⁇ _4-alkoxy-C ⁇ _4-alkyl, oxo, oxime, O-C ⁇ _4-alkyloxime, hydroxy, amino, Ci . ⁇ alkylamino, di-C ⁇ .4- alkylamino, acylamino and aminoacyl.
- R 3 , R 5 , R 7 and R 9 independently denote hydrogen, methyl, ethyl, propyl, i-propyl, butyl and benzyl.
- E in the above Formula (I) denotes an optionally substituted phenyl, indenyl, naphthyl, pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, pyranopyrrolyl, isoindazolyl, indoxazinyl, benzoxazolyl, anthianilyl,
- Preferred compounds are those wherein Z is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl;
- More preferred compounds are those wherein Z is 2-pyridinyl, 2-pyrimidinyl, 2- pyrazinyl, 2-pyrrolidon-5-yl, or pyrrolidinyl.
- Preferred substituents for Z are methyl, ethyl, methoxy, methoxymethyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
- R', R", B2 and C2 are hydrogen, methyl and ethyl.
- Preferred groups E are optionally substituted phenyl, indenyl, naphthyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, pyrrolidinyl, pyridinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl or cinnolinyl.
- Alkyl groups may be straight or branched.
- the compounds of the present invention may contain one ore more asymmetric carbon atoms and may exist in racemic and optically active forms. All the compounds and diastereomers are contemplated to be within the scope of the present compounds. Especially preferred is:
- (2S)-2,5-Dihydro-3,6-diethoxyisopropylpyrazine (1 in Scheme 1) is coupled with an appropriate dielectrophile, such as 2 in Scheme 1 , using a strong base (such as butyllithium) in a suitable solvent (such as THF) to give in Scheme 1.
- a strong base such as butyllithium
- a suitable solvent such as THF
- compositions comprising as active ingredient one or more compounds of Formula (I) as herein before defined or physiologically compatible salts thereof, in association with a pharmaceutical carrier or excipient.
- the compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.
- the term "pharmaceutical” includes veterinary applications of the invention. These peptides may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
- Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
- Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
- the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the amount of solid carrier varies, but, preferably will be between about 20 mg to about 1 g per dosage unit.
- the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing and filling for hard gelatin capsule forms.
- Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules.
- Organ specific carrier systems may also be used.
- compositions of the peptides of this invention or derivatives thereof may be formulated as solutions of lyophilized powders for parenteral administration.
- Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
- the liquid formulation is generally a buffered, isotonic, aqueous solution.
- suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
- Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxycellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
- a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
- excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols
- the pulverized powders may also be compounded with oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
- Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propellant or provided with means for manual compression.
- Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) or of the salt thereof.
- a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition as hereinbefore defined to a subject. No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
- the murine bone marrow derived from stromal cell line C6.4 is grown in 12 well pates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell free supernatants are collected 18 hours later. Supernatants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.
- HSF hematopoietic synergistic factor
- Bone marrow cells are obtained from C57B 1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supernatants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.
- mice Female C57B 1 mice are administered test compound PO daily for 8 days.
- Resident peritoneal exudate cells (PEC) utilized ex vivo from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin and antibiotics within 2-4 hours following the last injection.
- Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37 °C (5% CO2) and removing nonadherent cells by washing the wells with warm buffer.
- SOD superoxide dismutase-inhibitable
- PMA phorbol myristate acetate
- nmoles of cytochrome c reduced /well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37 °C (5% CO2).
- the amount of SOD-inhibitable cytochrome c reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control group.
- Picolinic acid (0.80 g, 6.48 mmol) was suspended in 30 ml dichloromethane and a solution of l,4-Bis-(2-amino-2-ethyloxycarbonyl-(2R)-ethyl)-benzene (1.00 g, 3.24 mmol) in 10 ml dichloromethane was added.
- the clear solution was cooled to 0°C and HOBt (1.26 g, 8 mmol) and DCC (1.33 g, 6.48 mmol) were added.
- the reaction mixture came to room temperature overnight and was extracted with 4% NaHCO solution. The combined organic layers were dried over MgSO4, filtered and the solvent was removed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Novel compounds of general formula (I) which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
Description
HEMOREGULATORY COMPOUNDS
Field of the Invention
The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
Background ofthe Invention
The haematopoietic system is a life-long cell renewal process whereby a defined stem cell population gives rise to a larger population of mature, differentiated blood cells (Dexter TM. Stem cells in normal growth and disease, Br Med J 1987; 195:1192-1194) of at least nine different cell lineages (erythrocytes, platelets, eosinophils, basophils, neutrophils, monocytes/macrophages, osteoclastes and lymphocytes) (Metcalf D. The Molecular Control of Blood Cells, 1988; Harvard University Press, Cambridge, MA). The stem cells are also ultimately responsible for regenerating the bone marrow following treatment with cytotoxic agents or following bone marrow transplantation.
The major dose-limiting toxicities of most standard anti-neoplastic drugs are related to bone marrow suppression, which if severe and prolonged, can give rise to life- threatening infectious and haemorrhagic complications. Myelosuppression is predictable and has been reported to be dose-limiting in greater than 50% of single- agent Phase I trials cytotoxic compounds (Merrouche Y, Catimel G, Clavel M. Haematopoietic growth factors and chemoprotectants; should we move toward a two-step process for phase I trials in oncology? Ann Oncol 1993; 4:471-474). The risk of infection is directly related to the degree of myelosuppression as measured by the severity and duration of neutropenia (Brody GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infections with acute leukemia. Ann In Med 1965; 64:328-334).
The control of haematopoiesis involves the interplay of a variety of cytokines and growth factors during various stages of the haematopoietic cascade, including early pluripotent stem cells and mature circulating effector cells. These regulatory molecules include granulocyte colony stimulating factor (G-CSF), granulocyte- macrophage stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), and a variety of interleukines which have overlapping, additive and synergistic actions which play major roles in host defence. Mechanistically, this is accomplished by enhancing the production of granulocytes and macrophages, as well as by the activation of effector cell functions (Moore MAS. Haematopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surveys 1990; 9:7-80). These co-ordinated activities support optimal host defences which are necessary for fighting bacterial, viral and fungal infections.
Strategies to prevent or reduce the severity of neutropenia and myelotoxicity include the use of haematopoietic growth factors and/or other haematopoietic cytokines. Such treatments are becoming common practice, in that they offer the potential of increased doses of cytotoxic agents that may improve the therapeutic efficacy if antineoplastic agents, and reduce the morbidity associated with their use (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342: 153-157). Clinical studies have demonstrated the G-, GM- and/or M-CSF may reduce the duration of neutropenia, accelerate myeloid recovery and reduce neutropenia-associated infections and other infectious complications in patients with malignancies who are receiving cytotoxic chemotherapy or in high infectious-risk patients following bone marrow transplantation (Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors, Lancet 1993; 342:153-157 and Munn DH, Cheung NKV. Preclinical and clinical studies of macrophage colony- stimulating factor. Semin Oncol 1992; 19:395-407).
We have now found certain novel compounds which have a stimulative effect on myelopoietic cells and are useful in the treatment and prevention of viral, fungal and bacterial diseases.
Summary of the Invention
This invention comprises compounds, hereinafter represented as Formula (I), which have hemoregulatory activities and can be used to stimulate haematopoiesis and in the prevention and treatment of bacterial, viral and fungal diseases. These compounds are useful in the restoration of leukocytes in patients with lowered cell counts resulting from a variety of clinical situations, such as surgical induced myelosuppression, AIDS, ARDS, congenital yelodysplacis, bone marrow and organ transplants; in the protection of patients with leukopenia from infection; in the treatment of severely burned patients and in the amelioration ofthe myelosuppression observed with some cell-cycle specific antiviral agents and in the treatment of infections in patients who have had bone marrow transplants, especially those with graft versus host disease, in the treatment of tuberculosis and in the treatment of fevers of unknown origin in humans and animals. The compounds are also useful in the treatment and prevention of viral, fungal and bacterial diseases, particularly Candida, Herpes and hepatitis in both immunosuppressed and "normal" subjects.
These compounds may also be used in combination with the monomers of co- pending U.S. Application No. 07/799,465 and U.S. Patent No. 4,499,081, incorporated by reference herein, to provide alternating peaks of high and low activity in the bone marrow cells, thus augmenting the natural circadian rhythm of haematopoiesis. In this way, cytostatic therapy can be given at periods of low bone marrow activity, thus reducing the risk of bone marrow damage, while regeneration will be promoted by the succeeding peak of activity.
This invention is also a pharmaceutical composition, which comprises a compound of Formula (I) and a pharmaceutically acceptable carrier.
This invention further constitutes a method for stimulating the myelopoietic system of an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
This invention also constitutes a method for preventing and treating viral, fungal and bacterial infections including sepsis in immunosuppressed and normal animals, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of Formula (I).
Detailed Description of the Invention
The compounds of the invention are represented by structural Formula I
in which:
Ai and A2 independently from each other denote a group Z-(CH2)k-(NR"')q, wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cj_4alkyl, F, Cl, Br, I, Cj_4 alkoxy, (CH2)mR4, oxo, oxime, O-Cj. 4alkyloxime, hydroxy, N(R3)2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded;
R' and R" are independently hydrogen, Cι_4alkylC(O)R4, Cι _4alkyl or R' and R are benzyl which is optionally substituted by one or two Cj^alkyl, C1_4alkoxy, F, Cl, I, Br, OH, or N(R3)2; k is an integer from 0 to 4;
R'" denotes Hydrogen, Cι_4-alkyl or Cι.4-alkylcarboxylic acid; q is an integer from 0 to 1 ; Q denotes a group
Bi denotes halogen, -(CH2)m-CN, -(CH2)m+i-R2, -(CH2)m-R3,- (CH2)m- COR2 or -(CH2)m-COR3; where
R2 denotes - OR3, -N(R3)2, - SR3; R3 is independently hydrogen, C -C4-alkyl or benzyl; m is an integer from 0 to 4;
Ci denotes halogen, -(CH2)n-CN, -(CH2)n+l-R4, -(CH2)n-R5, -(CH2)n-COR4 or -(CH2)n-COR5; where
R4 is independently -OR5, -N(R5)2, - SR5; R5 is independently hydrogen, Cι-C4-alkyl or benzyl and n is an integer from 0 to 4;
B2 denotes halogen, -(CH2)p-CN, -(CH2)p+ι-R6, -(CH2)p-R7, -(CH2)p-COR6 or -(CH2)p-COR7;
R6 is independently -OR7, -N(R7)2, -SR7; R7 is independently hydrogen, C j -C4-alkyl or benzyl; p is independently an integer from 0 to 4;
C2 denotes halogen, -(CH2)ι-CN, -(CH2)ι+ι-R8, -(CH2)ι-R9, -(CH2)I-COR8 or -(CH2)ι-COR9;
R8 is independently -OR9, -N(R9)2, -SR9; R9 is independently hydrogen, C i -C4-alkyl or benzyl ;
1 is an integer from 0 to 4;
D denotes -(CH2)x-E-(CH2)y-; wherein
E denotes a mono- or bicyclic aromatic or nonaromatic ring system consisting of 5 - 10 carbon atoms containing up to 4 heteroatoms N, O or S in the
ring, which is optionally mono-, poly or mixed substituted by alkyl, alkoxy, oxo, alkoxyalky, hydroxy, amino or dialkylamino and x and y independently denote an integer from 0 to 5; with the proviso that
Bi is not identical to Ci and B2 is not identical to C2- and Ai ≠ A2 ;
Bι ≠ B2;
Cι ≠ C2;
B2 ≠ C2;
and pharmaceutically acceptable salts thereof.
Z in the above Formula (I) denotes an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, piperidyl, tetrazolyl, quinuclidinyl, azetidinyl, or purinyl;
Possible substituents for Z are C1.4-a.kyl, Cι.4-alko y, Cι_4-alkoxy-Cι_4-alkyl, oxo, oxime, O-Cι_4-alkyloxime, hydroxy, amino, Ci .^alkylamino, di-Cι.4- alkylamino, acylamino and aminoacyl.
R3, R5, R7 and R9 independently denote hydrogen, methyl, ethyl, propyl, i-propyl, butyl and benzyl.
E in the above Formula (I) denotes an optionally substituted phenyl, indenyl, naphthyl, pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl,
pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, morpholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, pyranopyrrolyl, isoindazolyl, indoxazinyl, benzoxazolyl, anthianilyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl or benzoxazinyl.
Preferred compounds are those wherein Z is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydroquinolinyl, azetidinyl, or pyrrolidinyl;
More preferred compounds are those wherein Z is 2-pyridinyl, 2-pyrimidinyl, 2- pyrazinyl, 2-pyrrolidon-5-yl, or pyrrolidinyl.
Preferred substituents for Z are methyl, ethyl, methoxy, methoxymethyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
Preferred groups R', R", B2 and C2 are hydrogen, methyl and ethyl.
Preferred groups E are optionally substituted phenyl, indenyl, naphthyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, pyrrolidinyl, pyridinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl or cinnolinyl.
Alkyl groups may be straight or branched.
The compounds of the present invention may contain one ore more asymmetric carbon atoms and may exist in racemic and optically active forms. All the compounds and diastereomers are contemplated to be within the scope of the present compounds.
Especially preferred is:
Methods of Preparation
Compounds of Formula (I) wherein E, R', R", R'", Cγ, C2, B2, Aj, A2, Z, k, 1, m, n, p, x and y are defined as in Formula (I) are prepared by methods analogous to those described in Scheme 1.
Scheme 1
6 2 a) butyllithium, THF; b) 0,1M HCl, dioxane/ethanol/water; c) DCC, HOBt, CH2CI2; d) LiOH, dioxane/ethanol/water
(2S)-2,5-Dihydro-3,6-diethoxyisopropylpyrazine (1 in Scheme 1) is coupled with an appropriate dielectrophile, such as 2 in Scheme 1 , using a strong base (such as butyllithium) in a suitable solvent (such as THF) to give in Scheme 1. Hydrolysis and ring-opening under standard acidic conditions (such as 0,1 M HCl) in a suitable solvent (such as dioxane/ethanol/water) leads to a diamine, such as 4 in Scheme 1 , which is then acylated with appropriate heterocyclic acids, such as 5_ in Scheme 1,
using an activating agent (such as DCC) and a strong base (such as HOBt) in an aprotic polar solvent (such as CH2CI2). Optionable hydrolysis of the ester under standard basic conditions (such as LiOH) in a suitable solvent (such as dioxane/ethanol/water) furnishes the product 1 in Scheme 1.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with pharmaceutical practice as a pharmaceutical composition.
According to a still further feature of the present invention there are provided pharmaceutical compositions comprising as active ingredient one or more compounds of Formula (I) as herein before defined or physiologically compatible salts thereof, in association with a pharmaceutical carrier or excipient. The compositions according to the invention may be presented for example, in a form suitable for oral, nasal, parenteral or rectal administration.
As used herein, the term "pharmaceutical" includes veterinary applications of the invention. These peptides may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies, but, preferably will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing and filling for hard gelatin capsule forms. Capsules containing one or several active ingredients may be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and filling the mixture into gelatin capsules. Organ specific carrier systems may also be used.
Alternately pharmaceutical compositions of the peptides of this invention or derivatives thereof, may be formulated as solutions of lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration and contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxycellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
For rectal administration, a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository. The pulverized powders may also be compounded with oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
Nasal sprays may be formulated similarly in aqueous solution and packed into spray containers either with an aerosol propellant or provided with means for manual compression.
Dosage units containing the compounds of this invention preferably contain 0.05-50 mg, for example 0.05-5 mg of the compound of Formula (I) or of the salt thereof.
According to a still further feature of the present invention there is provided a method of stimulation of myelopoiesis which comprises administering an effective amount of a pharmaceutical composition as hereinbefore defined to a subject.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) is demonstrated by the following tests.
Induction of Hematopoietic Synergistic Activity in Stromal Cells
The murine bone marrow derived from stromal cell line C6.4 is grown in 12 well pates in RPMI 1640 with 10% FBS. Upon reaching confluence, the C6.4 cells are washed and the media exchanged with fresh RPMI 1640 without FBS. Confluent cell layers of murine C6.4 cells are treated with compound. Cell free supernatants are collected 18 hours later. Supernatants are fractionated with a Centricon-30 molecular weight cut-off membrane. C6.4 cell hematopoietic synergistic factor (HSF) activity is measured in a murine CFU-C assay.
CFU-C Assay
Bone marrow cells are obtained from C57B 1/6 female mice and suspended in RPMI 1640 with 10% FBS. Bone marrow cells (7.5E+4 cells/mL) are cultured with sub optimal levels of CFU plus dilutions of test C6.4 cell 30K-E supernatants from above in a standard murine soft agar CFU-C assay. Cell aggregates >50 cells are counted as colonies. The number of agar colonies counted is proportional to the amount of HSF present within the C6.4 bone marrow stromal line supernatant.
Effector Cell Function Assay
Female C57B 1 mice are administered test compound PO daily for 8 days. Resident peritoneal exudate cells (PEC) utilized ex vivo from treated or untreated mice are harvested with cold calcium and magnesium-free DPBS supplemented with heparin and antibiotics within 2-4 hours following the last injection. Adherent PEM populations are prepared by incubating standardized PEC suspensions in microtiter dishes for 2 hours at 37 °C (5% CO2) and removing nonadherent cells by washing the wells with warm buffer.
The superoxide dismutase-inhibitable (SOD) superoxide released by effector cells in response to a in vitro stimulation by phorbol myristate acetate (PMA) (100-200 nM) or pre-opsonized (autologous sera) live C. albicans (E:T = 1: 10) are quantitated in a microtiter ferricytochrome c reduction assay. The assay is performed in the presence of 1% gelatin HBSS and 80 μM ferricytochrome c in a total volume of 200 μL/well. The nmoles of cytochrome c reduced /well is calculated from spectrophotometric readings (550 nm) taken following a 1 hour incubation at 37 °C (5% CO2). The amount of SOD-inhibitable cytochrome c reduced is determined by the inclusion of wells containing SOD (200 U/well). Baseline superoxide release is determined in the absence of stimuli. Experimental data are expressed as a percentage of the control group.
Example 1 l-("2-f2-pyridylcarbonylamino)-2-carboxy-(2R)-ethyl)-4-(2-ethyloxycarbonyl-2-(2- pyridylcarbonylamino)-('2R ethyl)-benzene
(2S)-2,5-Dihydro-3,6-diethoxyisopropylpyrazine (6.00 g; 28.31 mmol) was dissolved in THF (70 ml) and a 1.6 M solution of butyllithium in hexane was added at -78°C (17.7 ml; 28.31 mmol). After lh at -78°C a solution of the dielectrophile ( a,a'-dibromo-p-xylene, 3.8 g, 14.4 mmol) in 30 ml THF was added dropwise and the mixture came to -60 °C overnight. After hydrolysis the mixture was extracted with diethyl ether ( 3 x 300 ml) and the combined organic layers were dried over
MgSO4- After filtration and drying (Na2SO4), the solvents were removed on the rotary evaporator and the residue was dried under vacuum. Purification: flash chromatography: petrol ether/ethyl acetate 0.5/9. The purity and diasteromeric excess was determined by capillary GC. Yield: 1.8 g, 24 % (colourless oil)
Preparation of 1.4-Bis-(2-amino-2-ethyloxycarbonyl-(2R)-ethyl)-benzene
a,a'-Bis-((2S,5R)-2,5-dihydro-3,6-diethoxy-2-isopropyl-5-pyrazine)-p-xylene_(1.80 g; 3.40 mmol) was dissolved in dioxane (17 ml) and EtOH (34 ml) and a solution of cone. HCl (1.0 ml, 13.6 mmol) in water (34 ml) was added dropwise. The mixture was stirred overnight and the organic solvents were stripped off. A cone. aqueous ammonia solution was added until a pH of 9 was reached and the aqueous layer was extracted with chloroform (3 x 80 ml). The combined organic layers were
dried (MgSO4), filtered and the solvent was removed. Remaining ValOEt was removed by Kugelrohr distillation (room temperature, 0.05 Torr) to yield 1.16 g of l,4-Bis-(2-amino-2-ethyloxycarbonyl-(2R)-ethyl)-benzene (100%) as a pale yellow oil.
Preparation of 1.4-Bis-f 2-ethyloxycarbonyl-2-(2-pyridylcarbonylamino)-(2R)- ethvn-benzene
Picolinic acid (0.80 g, 6.48 mmol) was suspended in 30 ml dichloromethane and a solution of l,4-Bis-(2-amino-2-ethyloxycarbonyl-(2R)-ethyl)-benzene (1.00 g, 3.24 mmol) in 10 ml dichloromethane was added. The clear solution was cooled to 0°C and HOBt (1.26 g, 8 mmol) and DCC (1.33 g, 6.48 mmol) were added. The reaction mixture came to room temperature overnight and was extracted with 4% NaHCO solution. The combined organic layers were dried over MgSO4, filtered and the solvent was removed. The residue was purified by flash chromatography (silica gel; chloroform/methanol 50/1) to yield l,4-Bis-(2-ethyloxycarbonyl-2-(2- pyridylcarbonylamino)-(2R)-ethyl)-benzene (1.28 g, 76%) as a colourless oil.
Preparation of 1 -(2-(2-pyridylcarbonylamino)-2-carboxy-(2R)-ethyl)-4-(2-ethyloxy- carbonyl-2-(2-pyridylcarbonylamino)-(2R)-ethyI)-benzene
l,4-Bis-(2-ethyloxycarbonyl-2-(2-pyridylcarbonylamino)-(2R)-ethyl)-benzene (0.15 g, 0.29 mmol) was dissolved in a mixture of 2 ml dioxane, 2 ml EtOH and 2 ml water and cooled to 0°C. 1 N LiOH (0.17 ml, 0.17 mmol) was added and the mixture was stirred at 0°C. The organic solvents were stripped off and the residual solution was acidified to pH 2 by dropwise addition of 4 N HCl. The mixture was extracted with ethyl acetate ( 3x ) , the combined organic layers were dried over
MgSO4, filtered and the solvents were evaporated. The compound was purified by flash chromatography with chlorof orm/methanol/acetic acid 9/1/0.02.
Yield: 56 mg, 40 % > ΪH NMR(CDCl3)d: 8.50(m,4H), 8.11(m,2H), 7.81(m,2H), 7.38(m,2H), 7.10(m,4H), 5.00(m,2H), 4.10(m,2H), 3.20(m,4H), 1.13(t,3H,J=5.0Hz) 1 C { 1H} nmr(CDCl3)d: 176.48, 171.32, 164.31, 164.06, 149.28, 149.20, 148.29, 137.27, 134.84, 129.54, 126.38, 126.35, 122.33, 61.44, 53.54, 38.11, 37.43, 14.04 C26H26N4θ6 ;M = 490.52
Claims
We claim:
A compound of Formula (I)
in which:
A and A2 independently from each other denote a group Z-(CH2)k-(NR'")q. wherein Z is a 4 - 10 membered mono- or bicyclic heterocyclic ring system containing up to four heteroatoms N, O, S in the ring in which at least one heteroatom is N, and wherein the ring is substituted or unsubstituted by one or two Cι_4alkyl, F, Cl, Br, I, C1.4 alkoxy, (CH2)mR4, oxo, oxime, O-Cj. 4alkyloxime, hydroxy, N(R3)2, acylamino or aminoacyl groups, 8, 9, 10 membered monocyclic ring systems being excluded; R' and R" are independently hydrogen, Cι_4alkylC(O)R4, C^alkyl or R and R are benzyl which is optionally substituted by one or two Ci^alkyl, Cι_4alkoxy, F, Cl, I, Br, OH, or N(R3)2; k is an integer from 0 to 4;
R'" denotes Hydrogen, Cι_4-alkyl or Cι_4-alkylcarboxylic acid; q is an integer from 0 to 1 ;
Q denotes a group
B1 C1 wherein:
Bi denotes halogen, -(CH2)m-CN, -(CH2)m+l-R2, -(CH2)m-R3,- (CH2)m- COR2 or -(CH2)m-COR3; where R2 denotes - OR3, -N(R3)2, - SR3;
R3 is independently hydrogen, Cι-C4-alkyl or benzyl; m is an integer from 0 to 4;
Ci denotes halogen, -(CH2)n-CN, -(CH2)n+l-R4, -(CH2)n-R5, -(CH2)n- COR4 or -(CH2)n-COR5; R4 is independently -OR5, -N(R5)2, - SR5;
R5 is independently hydrogen, Cι-C4-alkyl or benzyl and n is an integer from 0 to 4;
B2 denotes halogen, -(CH2)p-CN, -(CH2)p+ι- 6, -(CH2)p-R7, -(CH2)p-COR6 or -(CH2)p-COR7; R6 is independently -OR7, -N(R7)2, -SR7;
R7 is independently hydrogen, C -C4-alkyl or benzyl; p is independently an integer from 0 to 4;
C2 denotes halogen, -(CH2)ι-CN, -(CH2)ι+ι-R8, -(CH2)ι-R9, -(CH2)ι-COR8 or -(CH2)ι-COR9; R8 is independently -OR9, -N(R9)2, -SR9,
R9 is independently hydrogen, Cι-C4-alkyl or benzyl;
1 is an integer from 0 to 4;
D denotes -(CH2)x-E-(CH2)y-'> wherein
E denotes a mono- or bicyclic aromatic or nonaromatic ring system consisting of 5 - 10 carbon atoms containing up to 4 heteroatoms N, O or S in the ring, which is optionally mono-, poly or mixed substituted by alkyl, alkoxy, oxo, alkoxyalky, hydroxy, amino or dialkylamino and x and y independently denote an integer from 0 to 5; with the proviso that
Bi is not identical to Ci and B2 is not identical to C2- and Ai ≠ A ;
Bι ≠ B2;
Cι ≠ C2; 
> B2 ≠ C2;
and pharmaceutically acceptable salts thereof.
2. A compound of Claim 1 wherein Z is an optionally substituted pyrrolyl, isopyrrolyl, pyrazolyl, isoimidazolyl, triazolyl, iosxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, piperazinyl, triazinyl, moφholinyl, indolyl, indoleninyl, isobenzazolyl, pyrindinyl, ioindazolyl, indoxazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, indolinyl, pyrrolidonyl, imidazolyl, imidazolidinyl, imidazolinyl, piperidyl, tetrazolyl, quinuclidinyl, azetidinyl, or purinyl;
3. Compounds according to claim 1, wherein Z is an optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, tetrahydro¬ quinolinyl, azetidinyl, or pyrrolidinyl.
4. Compounds according to Claim 2 wherein Z is optionally mono-, poly- or mixed substituted by Cι_4-alkyl, Cι_4-alkoxy, Cι_4-alkoxy-Cι_4-alkyl, oxo, oxime, O-C i .4-alkyloxime, hydroxy, amino, C 1.4-alkylamino, di-C 1.4- alkylamino, acylamino and aminoacyl.
5. Compounds according to Claim 3 wherein Z is optionally mono-, poly- or mixed substituted by methyl, ethyl, methoxy, methoxymethyl, oxo, oxime, hydroxy, amino, ethylamino or dimethylamino.
6. Compounds according to claim 1 wherein R' and R" independently from each other denote hydrogen, methyl, ethyl, propyl, butyl, Cι_4-alkylcarboxylic acid or C2-4-alkylhydroxy.
7. Compounds according to Claim 1 wherein Bj denotes halogen, -
(CH2)m-CN, -(CH2)m+ι-R2 -(CH2)m-R3, -(CH2)m-COR2 or -(CH2)m-COR3, where R2 denotes -OR3, -NR32, - SR3, and R3 is hydrogen, methyl, ethyl, propyl, i-propyl, butyl or benzyl and m is an integer from 0 to 4.
8. Compounds according to Claim 1 wherein C i denotes halogen, -
(CH2)n-CN, -(CH2)n+l-R4, -(CH2)n-R5, -(CH2)n-COR4 or -(CH2)n-COR5, where R4 denotes -OR5, -NR 2, -SR5, and R5 is hydrogen, methyl, ethyl, propyl, i- propyl, butyl or benzyl and n is an integer from 0 to 4.
9. Compounds according to Claim 1 wherein B2 denotes halogen, -
(CH2)p-CN, -(CH2)p+i-R6, -(CH2)p-R7, -(CH2)p-COR6 or -(CH2)p-COR7, where R^ denotes -OR7, -NR72, -SR7, and R7 is hydrogen, methyl, ethyl, propyl, i- propyl, butyl or benzyl and p is an integer from 0 to 4.
10. Compounds according to Claim 1 wherein C2 denotes halogen, -
(CH2)ι-CN, -(CH2)ι+ι-R8, -(CH2)ι-R9, -(CH2)ι-COR8 or -(CH2)ι-COR9, where R8 denotes -OR9, -NR92, -SR9, and R9 is hydrogen, methyl, ethyl, propyl, i- propyl, butyl or benzyl and 1 is an integer from 0 to 4.
11. Compounds according to Claim 1 wherein D denotes -(CH2)X-E-
(CH2)y-, wherein E denotes a mono- or bicyclic aromatic or nonaromatic ring system consisting of 5 - 10 carbon atoms containing up to 4 heteroatoms N, O or S in the ring, which is optionally mono-, poly or mixed substituted by alkyl, alkoxy, alkoxyalky, hydroxy, amino or dialkylamino, 7, 8, 9, 10 membered moncyclic ring sytems being excluded, and x and y independently denote an integer from 0 to 5.
12. A compound of Claim 1 which is: l-(2-(2-pyridylcarbonylamino)-2-carboxy-(2R)-ethyl)-4-(2-ethyloxy- carbonyl-2-(2-pyridylcarbonylamino)-(2R)-ethyl)-benzene.
13. Process for producing a compound as claimed in claim 1, said process comprising a) reacting one equivalent of a suitably substituted 2,5-dihydropyrazine with one equivalent of an appropriate dielectrophile; b) transforming a functional group into an amine; c) acylating this amine with heterocyclic acids; d) hydrolyzing and opening of the pyrazine-ring; e) acylating the resulting amine with heterocyclic acids; f) optionally reducing and/or oxydizing any functional groups and/or removing any remaining protecting groups, and g) optionally forming a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.
15. A method of stimulating the myelopoietic system which comprises administering to a subject in need thereof, an effective amount to stimulate said myelopoietic system of a compound Claim 1.
16. A method of preventing or treating viral, fungal and bacterial infections which comprises administering to a subject in need thereof, an effective amount of a compound of Claim 1.
17. A method of preventing or treating sepsis which comprises administering to a subject in need thereof, an effective amount of a compound of Claim 1.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/068,247 US6197793B1 (en) | 1995-11-13 | 1996-11-12 | Hemoregulatory compounds |
| JP9518960A JP2000500747A (en) | 1995-11-13 | 1996-11-12 | Blood regulatory compounds |
| EP96938831A EP0861029A4 (en) | 1995-11-13 | 1996-11-12 | Hemoregulatory compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US657495P | 1995-11-13 | 1995-11-13 | |
| US60/006,574 | 1995-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997017850A1 true WO1997017850A1 (en) | 1997-05-22 |
Family
ID=21721552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/018008 WO1997017850A1 (en) | 1995-11-13 | 1996-11-12 | Hemoregulatory compounds |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6197793B1 (en) |
| EP (1) | EP0861029A4 (en) |
| JP (1) | JP2000500747A (en) |
| WO (1) | WO1997017850A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998032738A1 (en) * | 1997-01-27 | 1998-07-30 | Nycomed Austria Gmbh | New compounds with hemoregulating effect |
| EP0861078A1 (en) * | 1995-11-13 | 1998-09-02 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0861080A1 (en) * | 1995-11-13 | 1998-09-02 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0874638A1 (en) * | 1995-11-13 | 1998-11-04 | Smithkline Beecham Corporation | Hemoregulatory compounds |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127361A1 (en) * | 2002-05-14 | 2004-07-01 | Ying Song | Pyridinyl fused bicyclic amides as fungicides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734406A (en) * | 1985-03-13 | 1988-03-29 | Hoechst Aktiengesellschaft | 3-pyridylmethylnaphthyl derivatives and composition containing them useful to inhibit thromboxane synthetase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0701446A4 (en) * | 1993-05-24 | 1997-04-23 | Smithkline Beecham Corp | Hemoregulatory peptides |
| WO1997018214A1 (en) * | 1995-11-03 | 1997-05-22 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| JP2000500456A (en) * | 1995-11-13 | 2000-01-18 | スミスクライン・ビーチャム・コーポレイション | Blood regulatory compounds |
| EP0861078A4 (en) * | 1995-11-13 | 1999-03-17 | Smithkline Beecham Corp | Hemoregulatory compounds |
-
1996
- 1996-11-12 US US09/068,247 patent/US6197793B1/en not_active Expired - Fee Related
- 1996-11-12 EP EP96938831A patent/EP0861029A4/en not_active Withdrawn
- 1996-11-12 WO PCT/US1996/018008 patent/WO1997017850A1/en not_active Application Discontinuation
- 1996-11-12 JP JP9518960A patent/JP2000500747A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734406A (en) * | 1985-03-13 | 1988-03-29 | Hoechst Aktiengesellschaft | 3-pyridylmethylnaphthyl derivatives and composition containing them useful to inhibit thromboxane synthetase |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861078A1 (en) * | 1995-11-13 | 1998-09-02 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0861080A1 (en) * | 1995-11-13 | 1998-09-02 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0874638A1 (en) * | 1995-11-13 | 1998-11-04 | Smithkline Beecham Corporation | Hemoregulatory compounds |
| EP0861080A4 (en) * | 1995-11-13 | 1999-01-20 | Smithkline Beecham Corp | Hemoregulatory compounds |
| EP0861078A4 (en) * | 1995-11-13 | 1999-03-17 | Smithkline Beecham Corp | Hemoregulatory compounds |
| EP0874638A4 (en) * | 1995-11-13 | 1999-07-21 | Smithkline Beecham Corp | Hemoregulatory compounds |
| WO1998032738A1 (en) * | 1997-01-27 | 1998-07-30 | Nycomed Austria Gmbh | New compounds with hemoregulating effect |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0861029A4 (en) | 1999-02-17 |
| JP2000500747A (en) | 2000-01-25 |
| US6197793B1 (en) | 2001-03-06 |
| EP0861029A1 (en) | 1998-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6077857A (en) | Hemoregulatory compounds | |
| US6197793B1 (en) | Hemoregulatory compounds | |
| US6191146B1 (en) | Hemoregulatory compounds | |
| US6194413B1 (en) | Hemoregulatory compounds | |
| US6200986B1 (en) | Hemoregulatory compounds | |
| US6077855A (en) | Hemoregulatory compounds | |
| US6030989A (en) | Hemoregulatory compounds | |
| US6051584A (en) | Hemoregulatory compounds | |
| US6107309A (en) | Hemoregulatory compounds | |
| US6114357A (en) | Hemoregulatory compounds | |
| WO1997017985A1 (en) | Hemoregulatory compounds | |
| EP0861077B1 (en) | Hemoregulatory compounds | |
| US6077856A (en) | Hemoregulatory compounds | |
| WO1997017963A1 (en) | Hemoregulatory compounds | |
| WO1997018210A1 (en) | Hemoregulatory compounds | |
| MXPA98003773A (en) | Hemoregulated compounds | |
| CA2237301A1 (en) | Hemoregulatory compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 518960 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1996938831 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996938831 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09068247 Country of ref document: US |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996938831 Country of ref document: EP |